DS-8201a + T-DM1
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-Positive Primary Breast Cancer
Conditions
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Trial Timeline
Dec 4, 2020 → Dec 31, 2030
NCT ID
NCT04622319About DS-8201a + T-DM1
DS-8201a + T-DM1 is a phase 3 stage product being developed by Daiichi Sankyo for HER2-Positive Primary Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04622319. Target conditions include HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer.
What happened to similar drugs?
0 of 14 similar drugs in HER2-Positive Primary Breast Cancer were approved
Approved (0) Terminated (0) Active (14)
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04622319 | Phase 3 | Active |
Competing Products
20 competing products in HER2-Positive Primary Breast Cancer